Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2025-03-27 Earnings Release
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Earnings Release Classification · 85% confidence The document is the company’s “Annual Results Announcement for the year ended December 31, 2024” filed on the Hong Kong Exchange. It provides audited annual results, business highlights, financial highlights, key events after period end, and management discussion and analysis. This is the initial public release of the full‐year results rather than the complete Annual Report (10-K) or statutory accounts. By our taxonomy, the initial public release of periodical financial results—whether quarterly, half‐year, or annual—is classified as an Earnings Release (ER). FY 2024
2025-03-27 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 85% confidence The document is a notice of a board meeting to consider and approve annual results and dividend recommendations. It does not itself announce results, changes in board composition, or contain the actual financial report. It is a general regulatory announcement on HKEX that does not fit other specific categories, so it falls under the fallback “Regulatory Filings” (RNS).
2025-03-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Regulatory Filings Classification · 85% confidence The document is a mandatory monthly return under HKEX Chapter 19B detailing movements in authorised share capital, issued shares, treasury shares, and related confirmations. It is not a financial report, earnings release, or share issuance announcement per se but a listing‐rule compliance filing. It does not fit any specific category like share issue or share repurchase because no changes occurred; therefore it falls under the general “Regulatory Filings” fallback category.
2025-03-06 English
VOLUNTARY ANNOUNCEMENT UPDATE ON NEW DRUG APPLICATION OF MRG003
Regulatory Filings Classification · 80% confidence The document is a voluntary corporate announcement filed on the Hong Kong Exchange detailing an update on the company’s new drug application progress (withdrawal and re-submission of an NDA). It is not an AGM material, financial report, earnings release, M&A notice, dividend notice, or other specific category. It’s a miscellaneous regulatory announcement, thus best classified as Regulatory Filings (RNS).
2025-03-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 88% confidence The document is a mandatory monthly return (Form FF301) filed to the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing movements in share capital, issued shares, and depositary receipts for the month ended 31 January 2025. It is not an earnings release, annual or interim report, nor a specific transaction announcement, but rather a periodic regulatory listing filing. It does not fit any of the more narrowly defined categories, so it falls under the general regulatory filings fallback category.
2025-02-06 English
INSIDE INFORMATION ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR NOVEL ADC MRG007
Regulatory Filings Classification · 87% confidence The document is a Hong Kong Stock Exchange “inside information announcement” regarding an exclusive license agreement for a novel ADC with ArriVent BioPharma. It is neither a financial report (annual or interim), earnings release, M&A, share issue, dividend notice, nor any other specific category (e.g., management changes, proxy materials, ESG report). It does not present full financial statements or an investor presentation, nor is it a publication notice for a report. Therefore, it falls under the fallback category of Regulatory Filings (RNS) as a general regulatory announcement under Listing Rule 13.09.
2025-01-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.